BGB-15025

DRUG5 trials

Sponsors

Beigene Ltd., BeOne Medicines, BeiGene

Conditions

Advanced MalignanciesAdvanced Solid TumorMetastatic Non-small Cell Lung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Active, not recruitingNCT04649385

BeiGeneAdvanced Solid Tumor

Start: 2021-03-04End: 2026-05-16Updated: 2026-02-20

Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active, not recruitingNCT05635708

BeiGeneMetastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer

Start: 2023-03-07End: 2026-10-01Target: 400Updated: 2026-03-18

MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Active, not recruitingCTIS2022-502738-18-00

Beigene Ltd.Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer

Start: 2023-09-15Target: 22Updated: 2025-11-18

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

CompletedNCT06029127

BeiGeneNon-Small Cell Lung Cancer

Start: 2023-10-23End: 2024-12-31Updated: 2026-01-05

Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Active, not recruitingNCT04164199

BeOne MedicinesAdvanced Malignancies

Start: 2019-12-19End: 2026-07-01Updated: 2026-03-27

Related Papers

A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.

Journal of Clinical Oncology2025-05-28

A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2024-06-016 citations

Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)

Cancer Research2024-04-05

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.

2023-07-2010 citations

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Clinical Cancer Research2021-10-2944 citations